VIDEO: Stelara shows ‘remarkable durability’ in Crohn’s

In this exclusive video from UEG Week Virtual, William J. Sandborn, MD, from the University of California, San Diego, discusses the final results from the IM-UNITI long-term extension trial of Stelara in patients with Crohn’s disease.In the study, researchers found that nearly half of patients with CD who responded to Stelara (ustekinumab, Janssen) in induction were in remission after 5 years of maintenance treatment. Additionally, they found no new safety signals.Read More

Share on facebook
Share on twitter
Share on linkedin